Overcoming Barriers In Cell-Based Cancer Therapy

Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while delivering rapid remissions for hard‑to‑treat patients.

These AI Models Might Take Down Superbugs

In this week’s edition of The Prototype, we look at using AI to find new drugs, quantum biotechnology, the ROI of generative AI and more.

Walmart To Launch Clinical Research Sites In Shuttered Health Clinics

Walmart this spring will roll out clinical research sites in a limited number of stores and former shuttered clinic sites in an effort to increase patient access.

When Reform Reduces Competition: A Risk In PBM Regulation And How To Avoid It

PBM transparency reforms aim to lower drug costs, but their impact on competition depends on how they affect smaller and independent pharmacy benefit managers.

The Most Important Thing You Need To Know About End Of Life Planning

End of life decision making is not just about living wills. More important than specifying what you want is specifying who you want making decisions.

Insufficient Sleep Is A Growing Crisis

In a large study, almost 27.3% individuals reported they had some type of sleep disorder.

OpenEvidence Founder Doubles His Wealth As Medical AI Startup Hits $12 Billion Valuation

Daniel Nadler, the 42-year-old CEO and cofounder of OpenEvidence, is now worth $7.6 billion as his AI search tool surges in popularity among U.S. doctors.

New York City Nurses And Hospitals Dig In During Strike’s Second Week

In this week’s edition of InnovationRx, we look at why Yann LeCun’s AI startup is focused on healthcare, Epic’s new predictive tools, and more.

Measles Surges In The U.S. As Public Health Systems Falter

Measles is revealing fractures in our public health system and insurance disparities. Each case costs almost $250,000. Misinformation about vaccine safety is fueling the rise.

Reversing Blindness With Electronic Retinas

Electronic retinal implants such as the PRIMA system bypass damaged cells to restore partial central vision, bringing high‑tech artificial sight closer to everyday clinical reality.